An Artificial Intelligence application for drone-assisted 5G remote e-Health

Artificial intelligence (AI) algorithms are experiencing growing research interest due to their ability to improve decision making capabilities for promising applications in different economic sectors. The growing shift toward the Internet of Everything environments brought by devices embedded with sensors that can share information brings immense opportunity for new applications (apps). While these new apps thrive in resource-rich areas (i.e., capitals), neighboring cities that lack the resources and infrastructure to support them may be left behind. It is vital that new technologies can reach those who need them the most, especially healthcare-based. This article proposes an app-based approach for long-distance patient monitoring and care. The app would serve as a platform of communication between patients and healthcare staff, where the latter can send standardized video footage or pictures to the former (e.g., their primary care doctor). This feature is enhanced with a recurrent neural network algorithm as a validation tool for healthcare-related videos exchanged between patients and staff. Thus, the healthcare team does not need to check each video for validity, freeing their time for other activities

Critical skills needs and challenges for STEM/STEAM graduates increased employability and entrepreneurship in the solar energy sector

Energy produced by photovoltaic module (PVM) is poised to deliver the UN Sustainable Development Goal 7 (SDG-7) by 2030 and Net-Zero by 2050 but not until ample graduates with adequate Solar Energy Technology (SET) skills are produced by Higher education institutions (HEIs). Although PVM has witnessed significant penetration globally, the sustainability of the growth of the sector is challenged by attendant monotonic skilled labour shortages. The evolving growth imbalance is critical in the European Union (EU), limits her global competitiveness and necessitates the need to create wider awareness on the green technology to stimulate more production of solar energy sector (SES) specific skills graduates. Discussing the mismatch between the skills Europe needs and has in the SES, the study outlines key critical skills Science, Technology, Engineering and Mathematics (STEM) cum Arts (STEAM) graduates ought to possess to secure sector employment and the challenges limiting them from acquiring the competencies. The review is conducted via extensive study of relevant literature, analysis of interviews and observations. Academic, industrial, and entrepreneurial skills are identified as critical SES needs. Designing and running educational modules/curricula that embed the identified solar technology specialist skills on students and learners are proposed as vehicle to increase their employability and entrepreneurship. This study profiles trends and developments in the SES for stakeholders’ increased awareness while presenting the specialist skills in-demand for employment in the sector. The adoption of SET Training (SETechTra) curricula/modules by the EIs will substantially increase the production of industry-ready graduates whilst decreasing the SES skills gap

Development and characterization of phytosterol-enriched oil microcapsules for foodstuff application

Phytosterols are lipophilic compounds contained in plants and have several biological activities. The use of phytosterols in food fortification is hampered due to their high melting temperature, chalky taste, and low solubility in an aqueous system. Also, phytosterols are easily oxidized and are poorly absorbed by the human body. Formulation engineering coupled with microencapsulation could be used to overcome these problems. The aim of this study was to investigate the feasibility of encapsulating soybean oil enriched with phytosterols by spray-drying using ternary mixtures of health-promoting ingredients, whey protein isolate (WPI), inulin, and chitosan as carrier agents. The effect of different formulations and spray-drying conditions on the microencapsules properties, encapsulation efficiency, surface oil content, and oxidation stability were studied. It was found that spherical WPI-inulin-chitosan phytosterol-enriched soybean oil microcapsules with an average size below 50 μm could be produced with good encapsulation efficiency (85%), acceptable level of surface oil (11%), and water activity (0.2–0.4) that meet industrial requirements. However, the microcapsules showed very low oxidation stability with peroxide values reaching 101.7 meq O2/kg of oil just after production, and further investigations and optimization are required before any industrial application of this encapsulated system

Safety of intravenous high-dose dipyridamole echocardiography. The Echo-Persantine International Cooperative Study Group.

Clinical data on 10,451 high-dose (up to 0.84 mg/kg over 10 minutes) dipyridamole-echocardiography tests (DET) performed in 9,122 patients were prospectively collected from 33 echocardiographic laboratories, each contributing greater than 100 tests. All patients were studied for documented or suspected coronary artery disease (1,117 early [less than 18 days] after acute myocardial infarction and 293 had unstable angina). Significant side effects including major adverse reactions and minor but limiting side effects occurred in 113 patients (1.2%). Major adverse reactions occurred in 7 cases (0.07%). In 6 of these cases, adverse reactions were associated with echocardiographically assessed ischemia and included 1 prolonged cardiac asystole (complicated by acute myocardial infarction and coma, with death after 23 days), 1 short-lasting cardiac asystole, 2 myocardial infarctions, 1 pulmonary edema and 1 sustained ventricular tachycardia. In all 6 cases, the cardiologist-echocardiographer performing the study had a limited experience (less than 100 tests) with DET, and at off-line reading in 5 cases, the obvious echo-positivity preceded the onset of complications by 1 to 5 minutes. The only ischemia-independent major side effect was a short-lasting cardiac asystole that was reversed by aminophylline and atropine. Significant side effects associated with echocardiographically assessed ischemia occurred in 89 additional cases (21 with and 68 without concomitant echocardiographically assessed myocardial ischemia). The most frequent of these side effects was hypotension or bradycardia, or both, which occurred in 40 patients with negative and 6 with positive DET. In all cases, side effects promptly subsided after aminophylline. In 1,857 cases, the high dose was not given for echo-positivity before the eighth minute.(ABSTRACT TRUNCATED AT 250 WORDS

SAFETY OF INTRAVENOUS HIGH-DOSE DIPYRIDAMOLE ECHOCARDIOGRAPHY

Clinical data on 10,451 high-dose (up to 0.84 mg/kg over 10 minutes) dipyridamole-echocardiography tests (DET) performed in 9,122 patients were prospectively collected from 33 echocardiographic laboratories, each contributing >100 tests. All patients were studied for documented or suspected coronary artery disease (1,117 early [<18 days] after acute myocardial infarction and 293 had unstable angina). Significant side effects including major adverse reactions and minor but limiting side effects occurred in 113 patients (1.2%). Major adverse reactions occurred in 7 cases (0.07%). In 6 of these cases, adverse reactions were associated with echocardiographically assessed ischemia and included 1 prolonged cardiac asystole (complicated by acute myocardial infarction and coma, with death after 23 days), 1 short-lasting cardiac asystole, 2 myocardial infarctions, 1 pulmonary edema and 1 sustained ventricular tachycardia. In all 6 cases, the cardiologist-echocardiographer performing the study had a limited experience (<100 tests) with DET, and at off-line reading in 5 cases, the obvious echo-positivity preceded the onset of complications by 1 to 5 minutes. The only ischemia-independent major side effect was a short-lasting cardiac asystole that was reversed by aminophylline and atropine. Significant side effects associated with echocardiographically assessed ischemia occurred in 89 additional cases (21 with and 68 without concomitant echocardiographically assessed myocardial ischemia). The most frequent of these side effects was hypotension or bradycardia, or both, which occurred in 40 patients with negative and 6 with positive DET. In all cases, side effects promptly subsided after aminophylline. In 1,857 cases, the high dose was not given for echo-positivity before the eighth minute. In 60 cases, the full high dose was not given despite the echocardiographic negativity for limiting side effect, yielding an overall feasibility of high-dose DET of 99%. Aminophylline was routinely administered also at the end of negative tests. Noticeable side effects occurred in 17 cases. In 13 patients (7 with negative and 6 with positive DET) transient ST-segment elevation occurred 1 to 4 minutes after the onset of aminophylline infusion, accompanied by regional dyssynergy. All 13 patients had variant angina. Thus, high-dose DET is reasonably safe and well-tolerated, even early after acute myocardial infarction and in patients with unstable angina, when selectively used in patients in whom the lower dose did not induce either echocardiographic signs of ischemia or limiting side effects

Safety of intravenous high-dose dipyridamole echocardiography

Clinical data on 10,451 high-dose (up to 0.84 mg/kg over 10 minutes) dipyridamole-echocardiography tests (DET) performed in 9,122 patients were prospectively collected from 33 echocardiographic laboratories, each contributing greater than 100 tests. All patients were studied for documented or suspected coronary artery disease (1,117 early [less than 18 days] after acute myocardial infarction and 293 had unstable angina). Significant side effects including major adverse reactions and minor but limiting side effects occurred in 113 patients (1.2%). Major adverse reactions occurred in 7 cases (0.07%). In 6 of these cases, adverse reactions were associated with echocardiographically assessed ischemia and included 1 prolonged cardiac asystole (complicated by acute myocardial infarction and coma, with death after 23 days), 1 short-lasting cardiac asystole, 2 myocardial infarctions, 1 pulmonary edema and 1 sustained ventricular tachycardia. In all 6 cases, the cardiologist-echocardiographer performing the study had a limited experience (less than 100 tests) with DET, and at off-line reading in 5 cases, the obvious echo-positivity preceded the onset of complications by 1 to 5 minutes. The only ischemia-independent major side effect was a short-lasting cardiac asystole that was reversed by aminophylline and atropine. Significant side effects associated with echocardiographically assessed ischemia occurred in 89 additional cases (21 with and 68 without concomitant echocardiographically assessed myocardial ischemia). The most frequent of these side effects was hypotension or bradycardia, or both, which occurred in 40 patients with negative and 6 with positive DET. In all cases, side effects promptly subsided after aminophylline. In 1,857 cases, the high dose was not given for echo-positivity before the eighth minute.(ABSTRACT TRUNCATED AT 250 WORDS